

Washington State Health Care Authority Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

https://www.hca.wa.gov/about-hca/prescription-drug-program

October 14, 2019

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective January 1, 2020:

Newer Anticoagulant Drugs Reviewed 6/20/2018		Agency Coverage			
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP	
apixaban	Eliquis [®] tablet	No	See Apple	Yes	
dabigatran etexilate mesylate	Pradaxa [®] capsule	No	Health PDL	Yes	
The effect of this recommendation is no change to the PDL.					

Asthma Biologics reviewed 4/18/2018		Agency Coverage			
Ingredient Name	Label Name of Preferred	L&I	Medicaid	UMP	
	Product				
mepolizumab	Nucala® subcutaneous	No	See Apple	Yes	
	injection		<u>Health</u>		
omalizumab	Xolair [®] subcutaneous	No	<u>PDL</u>	Yes	
	injection				
The effect of this recommendation is to make Nucala® and Xolair® preferred on the WA PDL.					

CGRP Inhibitors reviewed 12/18/2018		Agency Coverage			
Ingredient Name	Label Name of Preferred	L&I	Medicaid	UMP	
	Product				
galcanezumab	Emgality [®] subcutaneous	No	See Apple	Yes	
	injection		<u>Health</u>		
			<u>PDL</u>		
The effect of this recommendation is to make Emgality® preferred on the WA PDL.					

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our <u>website</u>.

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Donna Sullivan

Chief Pharmacy Officer

Dunal Sullem.

Clinical Quality and Care Transformation

Washington State Health Care Authority